Biotech company Inovio released positive interim data from its Phase I clinical trial of INO-4800, its experimental vaccine against COVID-19.
INO-4800 is one of the experimental vaccines included in the U.S. government’s Operation Warp Speed that has a goal of having a vaccine available by January 2021. The vaccine was designed using the company’s proprietary DNA medicine platform. Inovio claims it is the only nucleic acid-based vaccine that is stable at room temperature for more than a year and doesn’t need to be frozen in transport or storage.
